In vitro and in vivo study of thymosin alpha1 biodegradable in situ forming poly(lactide-co-glycolide) implants

International Journal of Pharmaceutics

Volumn 397, Issue 1-2, 2010, Pages 122-129

  Liu, Qingfeng ^a   Zhang, He ^a   Zhou, Guichen ^a   Xie, Shaobo ^a   Zou, Hao ^a   Yu, Yuan ^a   Li, Guodong ^a   Sun, Duxin ^b   Zhang, Guoqing ^a   Lu, Ying ^a   Zhong, Yanqiang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Biocompatibility; Chitosan; In situ forming implants; PLGA; Thymosin alpha1

Indexed keywords

1 METHYL 2 PYRROLIDINONE; BOVINE SERUM ALBUMIN; CHITOSAN; CYCLOPHOSPHAMIDE; POLYGLACTIN; THYMOSIN ALPHA1; TRIACETIN;

ANIMAL EXPERIMENT; ARTICLE; BIODEGRADABLE IMPLANT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG RELEASE; ENCAPSULATION; FREEZE DRYING; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN; SPRAY DRYING; THYMUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; DELAYED-ACTION PREPARATIONS; DOSAGE FORMS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; FREEZE DRYING; MALE; MICE; MICE, INBRED BALB C; MICROTECHNOLOGY; MOLECULAR WEIGHT; PARTICLE SIZE; POLYGLACTIN 910; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SOLVENTS; THYMOSIN;

EID: 77955984933     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.07.015     Document Type: Article

References (31)

1. Astaneh R., Erfan M., Moghimi H., Mobedi H. Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior. J. Pharm. Sci. 2009, 98:135-145.
2. Astaneh R., Moghimi H.R., Erfan M., Mobedi H. Formulation of an injectable implant for peptide delivery and mechanistic study of the effect of polymer molecular weight on its release behavior. DARU 2006, 14:65-70.
3. Brodbeck K.J., DesNoyer J.R., McHugh A.J. Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. J. Control. Release 1999, 62:333-344.
4. Bujalance C., Moreno E., Jimenez-Valera M., Ruiz-Bravo A. A probiotic strain of Lactobacillus plantarum stimulates lymphocyte responses in immunologically intact and immunocompromised mice. Int. J. Food Microbiol. 2007, 113:28-34.
5. Chen J., Hu T., Zheng R. Antioxidant activities of Sophora subprosrate polysaccharide in immunosuppressed mice. Int. Immunopharmacol. 2007, 7:547-553.
6. Fan Y.Z., Chang H., Yu Y., Liu J., Wang R. Thymosin α1 suppresses proliferation and induces apoptosis in human leukemia cell lines. Peptides 2006, 27:2165-2173.
7. Ganguly S., Dash A.K. A novel in situ gel for sustained drug delivery and targeting. Int. J. Pharm. 2004, 276:83-92.
8. Garaci E., Pica F., Rasi G., Favalli C. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. Int. J. Immunopharmacol. 2000, 22:1067-1076.
9. Garaci E., Pica F., Vallebona P.S., Pierimarchi P., Mastino A., Matteucci C., Rasi G. Thymosin α1 in combination with cytokines and chemotherapy for the treatment of cancer. Int. Immunopharmacol. 2003, 3:1145-1150.
10. García-Contreras F., Nevárez-Sida A., Constantino-Casas P., Abud-Bastida F., Garduño-Espinosa J. Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1. Arch. Med. Res. 2006, 37:663-673.
11. Graham P.D., Brodbeck K.J., McHugh A.J. Phase inversion dynamics of PLGA solutions related to drug delivery. J. Control. Release 1999, 58:233-245.
12. Hatefi A., Amsden B. Biodegradable injectable in situ forming drug delivery systems. J. Control. Release 2002, 80:9-28.
13. He S., Yaszemski M.J., Yasko A.W., Engel P.S., Mikos A.G. Injectable biodegradable polymer composites based on poly(propylene fumarate) crosslinked with poly(ethylene glycol)-dimethacrylate. Biomaterials 2000, 21:2389-2394.
14. Huang Y., Chen Z., Zhou C., Yao H., Li M., Xu C. The modulation of thymosin alpha 1 in the maturation, differentiation and function of murine bone marrow-derived dendritic cells in the absence or presence of tumor necrosis factor-alpha. Int. Immunopharmacol. 2004, 4:539-546.
15. Kang F., Singh J. In vitro release of insulin and biocompatibility of in situ forming gel systems. Int. J. Pharm. 2005, 304:83-90.
16. Kang G.D., Cheon S.H., Khang G., Song S.C. Thermosensitive poly(organophosphazene) hydrogels for a controlled drug delivery. Eur. J. Pharm. Biopharm. 2006, 63:340-346.
17. + cells in an in vitro thymic epithelia organ coculture model. Int. J. Immunopharmacol. 1999, 21:15-26.
18. Königs M., Lenczyk M., Schwerdt G., Holzinger H., Gekle M., Humpf H.U. Cytotoxicity, metabolism and cellular uptake of the mycotoxin deoxynivalenol in human proximal tubule cells and lung fibroblasts in primary culture. Toxicology 2007, 240:48-59.
19. Li C.L., Zhang T., Saibara T., Nemoto Y., Ono M., Akisawa N., Iwasaki S., Maeda T., Onishi S. Thymosin α1 accelerates restoration of T cell-mediated neutralizing antibody response in immunocompromised hosts. Int. Immunopharmacol. 2002, 2:39-46.
20. Loo W.T.Y., Dou Y.D., Chou W.K.J., Wang M. Thymosin alpha 1 provides short-term and long-term benefits in the reimplantation of avulsed teeth: a double-blind randomized control pilot study. Am. J. Emerg. Med. 2008, 26:574-577.
21. Luan X., Bodmeier R. Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems. J. Control. Release 2006, 110:266-272.
22. Moody T.W., Tuthill C., Badamchian M., Goldstein A.L. Thymosin α1 inhibits mammary carcinogenesis in Fisher rats. Peptides 2002, 23:1011-1014.
23. Paul S., Sodhi A. Modulatory role of thymosin-alpha-1 in normal bone-marrow haematopoiesis and its effect on myelosuppression in T-cell lymphoma bearing mice. Immunol. Lett. 2002, 82:171-182.
24. Rafienia M., Emami S.H., Mirzadeh H., Mobedi H., Karbasi S. Influence of poly(lactide-co-glycolide) type and gamma irradiation on the betamethasone acetate release from the in situ forming systems. Curr. Drug Deliv. 2009, 6:184-191.
25. Ravivarapu H.B., Moyer K.L., Dunn R.L. Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. Int. J. Pharm. 2000, 194:181-191.
26. Rost K.L., Wierich W., Masayuki F., Tuthill C.W., Horwitz D.L., Herrmann W.M. Pharmacokinetics of thymosin α1 after subcutaneous injection of three different formulations in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 1999, 37:51-57.
27. Westhaus E., Messersmith P.B. Triggered release of calcium from lipid vesicles: a bioinspired strategy for rapid gelation of polysaccharide and protein hydrogels. Biomaterials 2001, 22:453-462.
28. Yang Y.F., Zhao W., Zhong Y.D., Yang Y.J., Shen L., Zhang N., Huang P. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res. 2008, 77:136-141.
29. + monocytes. Immunol. Lett. 2007, 110:110-120.
30. Zhang Y.M., Yang F., Yang Y.Q., Song F.L., Xu A.L. Recombinant interferon-alpha2b poly(lactic-co-glycolic acid) microspheres: pharmacokinetics-pharmacodynamics study in rhesus monkeys following intramuscular administration. Acta Pharmacol. Sin. 2008, 29:1370-1375.
31. Zhong Y., Zhang L., Ding A.G., Shenderova A., Zhu G., Pei P., Chen R.R., Mallery S.R., Mooney D.J., Schwendeman S.P. Rescue of SCID murine ischemic hindlimbs with pH-modified rhbFGF/poly(dl-lactic-co-glycolic acid) implants. J. Control. Release 2007, 122:331-337.